4547
KISSEI PHARMACEUTICAL CO.,LTD.
キッセイ薬品工業
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2021
69,044
Mar 2022
65,381
Mar 2023
67,493
Mar 2024
75,579
Mar 2025
88,330
Operating profit(million JPY)
Mar 2021
1,505
Mar 2022
-1,402
Mar 2023
-1,129
Mar 2024
4,017
Mar 2025
5,773
Operating profit margin(%)
Mar 2021
2.18
Mar 2022
-2.14
Mar 2023
-1.67
Mar 2024
5.31
Mar 2025
6.54
Profit before tax(million JPY)
Mar 2021
7,476
Mar 2022
16,507
Mar 2023
13,680
Mar 2024
14,449
Mar 2025
15,610
Profit(million JPY)
Mar 2021
5,285
Mar 2022
12,921
Mar 2023
10,528
Mar 2024
11,160
Mar 2025
11,961
Total assets(million JPY)
Mar 2021
268,861
Mar 2022
238,087
Mar 2023
221,200
Mar 2024
260,929
Mar 2025
244,059
Cash and cash equivalents(million JPY)
Mar 2021
43,447
Mar 2022
53,004
Mar 2023
48,884
Mar 2024
45,887
Mar 2025
48,158
Cash flows from operating activities(million JPY)
Mar 2021
-2,542
Mar 2022
1,533
Mar 2023
-6,679
Mar 2024
-1,677
Mar 2025
6,521
Cash flows from investing activities(million JPY)
Mar 2021
-9,329
Mar 2022
10,776
Mar 2023
6,001
Mar 2024
8,690
Mar 2025
4,952
Cash flows from financing activities(million JPY)
Mar 2021
-4,000
Mar 2022
-2,756
Mar 2023
-3,420
Mar 2024
-10,006
Mar 2025
-9,325
Return on equity(%)
Mar 2021
2.6
Mar 2022
6.1
Mar 2023
5.3
Mar 2024
5.4
Mar 2025
5.6
Equity ratio(%)
Mar 2021
81.6
Mar 2022
84.6
Mar 2023
87.7
Mar 2024
84.3
Mar 2025
85.6
Earnings per share(JPY per share)
Mar 2021
113.25
Mar 2022
280.2
Mar 2023
228.31
Mar 2024
246.61
Mar 2025
274.21
Net assets per share(JPY per share)
Mar 2021
4,755.74
Mar 2022
4,366.96
Mar 2023
4,204.64
Mar 2024
4,977.41
Mar 2025
4,882.71
Dividend per share(JPY per share)
Mar 2021
54
Mar 2022
56
Mar 2023
80
Mar 2024
82
Mar 2025
100
Payout ratio(%)
Mar 2021
47.68
Mar 2022
19.99
Mar 2023
35.04
Mar 2024
33.25
Mar 2025
36.47
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.